In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entelos Inc.

www.entelos.com

Latest From Entelos Inc.

Looking Forward to Pharma's Decade of Predictive Efficacy

Drug developers can now tap into an array of new preclinical technologies including some that give them the ability to interrogate compounds in a broad biological context-a systems biology approach. In this issue, we profile four start-ups with technologies designed to predict drugs' efficacy: Champions Biotechnology, Cytox, Immuneering and Rhenovia.
BioPharmaceutical

SimuGen Ltd.

SimuGen has developed an analysis system that includes a pre-packaged kit that customers can use to test their own compounds. Accompanying client management software then imports the data and sends it to SimuGen's servers for analysis. It produces a dose-response curve for every clinically significant toxicity and also ranks related compounds based on their toxicity profile, allowing medicinal chemists to evaluate potential leads. Finally, clustering analysis reveals how changes to the molecular structure could affect the toxicity profile. The product has been designed to work with relatively few biomarker genes, which simplifies the laboratory procedure and avoids platforms such as microarrays.
BioPharmaceutical Research and Development Strategies

Making Inroads in Predictive Toxicology

Given the current "Safety First" mind-set among regulators, it's not surprising that the field of predictive toxicology has been slow to gain traction. Despite significant progress in developing biomarkers, database tools, and other methods, pharma companies continue to rely heavily on traditional methods for assessing potential drug toxicities. Even if investors are shy now, many say that they will eventually be a beneficiary of predictive toxicology, and that comes as good news to start-ups in the space.
BioPharmaceutical Research and Development Strategies

European IPOs Hold Their Own

The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Entelos Inc.
  • Senior Management
  • Shawn M O'Connor, CEO
    Will Frederick, CFO
    Lyn Powel, PhD, VP, Scientific Model Dev.
    Mike Davies, VP, Sales
    Thomas Paterson, CTO
    Dominic John, PhD, VP, Mktg.
  • Contact Info
  • Entelos Inc.
    Phone: (650) 572-5400
    2121 South El Camino Real
    Ste. 600
    San Mateo, CA 94403
    USA
UsernamePublicRestriction

Register